University of California, Los Angeles

Telix Pharmaceuticals announces first patient dosed in Phase II trial of TLX250-CDx PET agent for recurrent clear cell renal cell carcinoma (ccRCC) post-surgery, led by UCLA's Professor Brian Shuch. The trial aims to compare TLX250-CDx PET/CT to conventional imaging in 91 patients, potentially expanding TLX250-CDx's use beyond localized ccRCC.

Telix Pharmaceuticals announces first patient dosed in Phase II trial of TLX250-CDx PET agent for recurrent clear cell renal cell carcinoma (ccRCC) post-surgery, led by UCLA's Professor Brian Shuch.

Telix Pharmaceuticals announced the first patient dosed in a Phase II trial of TLX250-CDx (89Zr-girentuximab) for recurrent clear cell renal cell carcinoma (ccRCC) post-surgery, comparing its diagnostic performance to conventional imaging. The Phase III ZIRCON trial showed TLX250-CDx's high sensitivity (86%) and specificity (87%) for ccRCC detection, with an expanded access program in the U.S., named patient programs in Europe, and a special access scheme in Australia.

Dr. Amar Kishan presented 2-year outcomes from the MIRAGE trial at the 2024 ASTRO meeting, showing MRI-guided stereotactic body radiotherapy significantly reduced grade 2+ genitourinary and gastrointestinal toxicity compared to CT-guided radiotherapy, with benefits persisting beyond the acute phase.

Good friendships are crucial for happiness among single young adults, according to a study by Lisa Walsh et al., published in PLOS One. The study found that satisfaction with friendships strongly correlates with overall happiness, with those least neurotic and most satisfied with friendships being the happiest.

UCLA researchers developed SLIViT, a deep-learning AI framework for analyzing complex medical scans, achieving accuracy comparable to clinical specialists. SLIViT outperforms specialized models and reduces analysis time by 5,000x, with potential for predictive disease forecasting.

Implantable brain-computer interfaces (BCIs) face regulatory challenges globally, with the US leading in development and regulation. UK neuroscientist Luke Bashford co-founded the National Consortium for Neurotechnology Regulation to address UK's inexperience with implantable BCIs. Despite US dominance, concerns about global access and representation persist, with Japan and Europe also navigating their regulatory landscapes. The FDA's established protocols and supportive environment contrast with the UK's and EU's more cautious approaches, highlighting differing perspectives on patient benefit and risk.

UCLA researchers developed a method to generate sarcoma organoids within a week post-surgery/biopsy for drug screening, identifying personalized treatments for 58% of patients. The study, published in *Cell Stem Cell*, screened 194 tumor samples from 126 sarcoma patients, revealing significant drug responses in 80.4% of cases. A clinical trial (NCT06064682) is underway to validate the assay's predictive power for osteosarcoma treatment.